<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132925" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Imdevimab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sherchan</surname>
            <given-names>Robin</given-names>
          </name>
          <aff>Baylor College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cannady, Jr</surname>
            <given-names>Preston</given-names>
          </name>
          <aff>Chicago Medical School/ Rosalind Franklin University of Medicine and science</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robin Sherchan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preston Cannady, Jr declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132925.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">As of January 24, 2022, according to the United States Food and Drug Association (FDA) fact sheet for imdevimab, "due to the high frequency of the Omicron variant, imdevimab&#x000a0;is not currently authorized for use in any U.S. region because of markedly reduced&#x000a0;activity against the omicron variant. This drug may not be administered for&#x000a0;treatment or post-exposure prevention of COVID-19 under the Emergency Use&#x000a0;Authorization until further notice by the Agency." This&#x000a0;topic is to be used only for a historical review of the development and use of this drug.</p>
        <p>Imdevimab is&#x000a0;a monoclonal antibody (mAb) against spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (COVID-19). It is&#x000a0;1 of the SARS-CoV-2 neutralizing antibodies proposed for use in the clinical management of COVID-19.<xref ref-type="bibr" rid="article-132925.r1">[1]</xref>&#x000a0;On 21st November 2020, imdevimab and casirivimab cocktail were authorized for emergency use by the United States Food and Drug Administration (FDA). These are investigational drugs not approved for any specific indication. FDA allowed these drugs only to be administered together. Imdevimab (REGN10987), and casirivimab (REGN10933) is also known as REGN-COV2 or Regeneron.&#x000a0;The combination drug has been shown to decrease viral load<italic toggle="yes">&#x000a0;</italic>and decrease the risk of hospitalization and emergency visits. It has also been shown to prevent virus-induced pathological sequelae when administered prophylactically or therapeutically in non-human primates.<xref ref-type="bibr" rid="article-132925.r1">[1]</xref><xref ref-type="bibr" rid="article-132925.r2">[2]</xref></p>
        <p>FDA authorized the drug cocktail to be used only in nonhospitalized patients&#x000a0;who meet&#x000a0;all&#x000a0;3 following criteria:</p>
        <list list-type="order">
          <list-item>
            <p>Age &#x02265;12 years and weight &#x02265;40 kg&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lab confirmed SARS-COV-2 infection</p>
          </list-item>
          <list-item>
            <p>Mild to moderate&#x000a0;symptoms, which were at higher risk of progression to severe disease or hospitalization<xref ref-type="bibr" rid="article-132925.r3">[3]</xref><xref ref-type="bibr" rid="article-132925.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>High-risk patients include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age &#x02265; 65 years</p>
          </list-item>
          <list-item>
            <p>Body mass index (BMI) &#x02265; 25 (If 12-17 years old - BMI &#x02265; 85th percentile for their age and gender)</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Diabetes.</p>
          </list-item>
          <list-item>
            <p>Immunosuppressive disease, currently on immunosuppressive treatment</p>
          </list-item>
          <list-item>
            <p>Cardiovascular disease (including congenital heart disease) or hypertension</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease (COPD), asthma, or other chronic respiratory diseases</p>
          </list-item>
          <list-item>
            <p>Sickle cell disease</p>
          </list-item>
          <list-item>
            <p>Neurodevelopmental disorders (eg, cerebral palsy)</p>
          </list-item>
          <list-item>
            <p>Medical device dependency (eg, tracheostomy, gastrostomy, positive pressure ventilation [not related to COVID-19])</p>
          </list-item>
        </list>
        <p>On June 3, 2021, the FDA updated the emergency use authorization (EUA), lowering the dosage of casirivimab and imdevimab to 600 mg each, an option for subcutaneous (SQ) administration. Another update on November 17, 2021, authorizing casirivimab and imdevimab (subcutaneously) for emergency use as post-exposure prophylaxis for COVID-19 in adults. It was recommended for patients who are vaccinated but not expected to mount adequate immune response or who are not fully vaccinated.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref>&#x000a0;It is recommended that the medication be started as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset. This is because active viral replication occurs between days 1&#x000a0;to 10 of symptoms, and these medications are&#x000a0;unlikely to be beneficial later. Monoclonal antibodies are likely associated with worse clinical outcomes when administered to hospitalized COVID-19 patients requiring high-flow oxygen or ventilator support. The imdevimab and casirivimab combination is not authorized in use for patients hospitalized or who require oxygen therapy for COVID-19.&#x000a0;Viral load reductions with intravenous (IV) and SQ appear similar, but data on SQ administration is limited.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref><xref ref-type="bibr" rid="article-132925.r6">[6]</xref></p>
        <p>This being said it is still reasonable to consider this drug combination in patients who test positive for SAR-COV-2 infection but are hospitalized due to some other indication. Patients or parents/caregivers have the option to accept or refuse this combination drug treatment. If treated with the drug cocktail, patients should continue to self-isolate and use infection control measures such as wearing masks, social distancing, disinfecting surfaces, and maintaining hand hygiene. Monoclonal antibodies&#x000a0;provide&#x000a0;rapid protection against infection, and protection can last for weeks to months. For patients receiving passive antibody therapy (eg, mAbs), the recommendation is to defer COVID-19 vaccination&#x000a0;for at least 90 days to avoid potential interference with the immune response.<xref ref-type="bibr" rid="article-132925.r7">[7]</xref>&#x000a0;Please review&#x000a0;the latest recommendations from the Centers for Disease Control and Prevention (CDC) and FDA on these medications. With new variants of the virus emerging, the indications and conditions for use are likely to change.</p>
      </sec>
      <sec id="article-132925.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Imdevimab is a recombinant neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody to the spike protein of SARS-CoV-2. It binds to the S1 subunit of the spike protein receptor-binding domain (RBD), blocking the attachment of&#x000a0;SARS-CoV-2&#x000a0;to the human ACE2 receptor. This prevents viral binding to the host cell, thereby preventing entry and replication of the virus, thus decreasing the viral load. Casirivimab binds to a non-overlapping portion of the spike protein RBD, similar to imdevimab, and the combination is theorized to limit the development of viral mutations. The cocktail of the&#x000a0;2 drugs was also found to have retained activity against the Alpha (B.1.1.7; UK), Beta (B.1.351; South Africa), Gamma (P.1; Brazil), Delta (B.1.617.2; India), Epsilon (B.1.427/429; California), Iota (B.1.526; New York), and Kappa (B.1.617.1; India) variants of SARS-CoV-2. The combination drug has no activity to the Omicron variant.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref><xref ref-type="bibr" rid="article-132925.r7">[7]</xref><xref ref-type="bibr" rid="article-132925.r8">[8]</xref></p>
      </sec>
      <sec id="article-132925.s3" sec-type="Administration">
        <title>Administration</title>
        <p>Imdevimab is not authorized to be used alone. The authorized dosage is a combination of imdevimab&#x000a0;600 mg + casirivimab 600 mg (was previously imdevimab&#x000a0;1200 mg + casirivimab&#x000a0;1200 mg) administered as a single intravenous (IV) infusion. There is an option for SQ administration as an alternative route if awaiting&#x000a0;intravenous infusion results in treatment delay, though&#x000a0;intravenous infusion is still preferred. The pediatric dose of the drug combination for age &#x02265; 12 years and weight &#x02265; 40 kg is the same as the adult dose. For post-exposure prophylaxis, imdevimab&#x000a0;600 mg + casirivimab&#x000a0;600 mg is administered together as a single&#x000a0;intravenous infusion (or SQ) as soon as possible following exposure to SARS-CoV-2. In case of ongoing exposure to SARS-CoV-2 for &#x0003e;4 weeks who are determined appropriate and vaccinated patients not expected to mount an adequate immune response, a subsequent dose of basiliximab 300 mg + imdevimab 300 mg once every 4 weeks can be repeated for the duration of ongoing exposure.</p>
        <p>Casirivimab and imdevimab come in individual single-use vials or co-formulated single vials. If individual vials are used, the drugs must be diluted and mixed by qualified healthcare professionals using an aseptic technique before infusion.<xref ref-type="bibr" rid="article-132925.r7">[7]</xref>&#x000a0;Once diluted, the solution should be used immediately. Storage after dilution can be in a refrigerator for up to 36 hours and at room temperature for up to 4 hours, including infusion time. While the infusion is ongoing&#x000a0;and up to 1 hour after completion, patients should be monitored for hypersensitivity reactions. The infusion should only occur in settings where healthcare providers have immediate access to medication to treat infusion-related reactions, such as anaphylaxis.&#x000a0;In cases of renal impairment, no dose adjustment is needed. Casirivimab and imdevimab are not eliminated intact in the urine, so renal impairment should not affect the exposure to the drugs. The effect on the pharmacokinetics of imdevimab in the presence of hepatic impairment is still unknown.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-132925.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>There is limited data available for adverse effects of imdevimab, but other adverse effects may come to light in the future. Adverse effects reported include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity including anaphylaxis&#x000a0;(8,000 mg dose)</p>
          </list-item>
          <list-item>
            <p>Infusion-related reactions included pyrexia, chills, urticaria, pruritus, abdominal pain, and flushing&#x000a0;(8,000 mg dose)</p>
          </list-item>
          <list-item>
            <p>Nausea and Vomiting (2,400 mg dose)<xref ref-type="bibr" rid="article-132925.r9">[9]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Due to the possibility of hypersensitivity, including anaphylaxis and infusion-related reactions, observation in the infusion center is advised for at least an&#x000a0;hour post-transfusion. If&#x000a0;there is a concern for an infusion-related reaction,&#x000a0;slow or stop the infusion and administer appropriate medications or supportive care.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref></p>
      </sec>
      <sec id="article-132925.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no absolute contraindications. Imdevimab and casirivimab combination is not authorized for use in patients with any of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age &#x0003c; 12 years and weight &#x0003c; 40 kg</p>
          </list-item>
          <list-item>
            <p>Hospitalized&#x000a0;due to COVID-19</p>
          </list-item>
          <list-item>
            <p>Requiring oxygen&#x000a0;support</p>
          </list-item>
          <list-item>
            <p>Requiring an increase in baseline oxygen flow due to COVID-19 in patients on chronic oxygen therapy due to underlying non-COVID-19 related comorbidities<xref ref-type="bibr" rid="article-132925.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132925.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Observation is required for infusion-related and hypersensitivity reactions, including anaphylaxis during and at least up to&#x000a0;1 hour following infusion completion.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref>&#x000a0;On arrival at the infusion center, clinical stability must be assessed as the patient's symptoms may have worsened since the initial plan for infusion was made. In cases where the patient's symptoms have worsened, the decision should be made if patients need to be evaluated further for the possible need for hospitalization. Patients must be monitored for at least 7 days for any serious adverse effects&#x000a0;following the infusion. Imdevimab and casirivimab are mAbs that are not renally excreted or metabolized by cytochrome P450 enzymes. Therefore, interactions with concomitant medications that are renally excreted or substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.<xref ref-type="bibr" rid="article-132925.r5">[5]</xref><xref ref-type="bibr" rid="article-132925.r7">[7]</xref></p>
      </sec>
      <sec id="article-132925.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The recommended dose of imdevimab is 600 mg, along with casirivimab 600 mg. In studies, doses up to 8 g (4000 mg of each drug) have been administered without dose-limiting toxicity.&#x000a0;In overdose situations, general supportive measures, including vital signs and clinical status monitoring, are recommended. There is no specific antidote for toxicity due to overdose.</p>
        <p>Pregnancy and lactation:</p>
        <list list-type="bullet">
          <list-item>
            <p>Imdevimab is a humanized monoclonal antibody (IgG1). Placental transfer of IgG depends on different factors, such as maternal serum IgG level and IgG subclass.<xref ref-type="bibr" rid="article-132925.r10">[10]</xref>&#x000a0;Further data are&#x000a0;needed to classify risk or benefit to the fetus.</p>
          </list-item>
          <list-item>
            <p>Maternal IgG is present in breast milk. Imdevimab&#x000a0;is a large protein molecule with a molecular weight of&#x000a0;about 144,000 Da, so the amount in milk is probably low. It is also likely partially destroyed in the infant's gastrointestinal tract. Therefore, absorption by the infant is likely low. No information is available&#x000a0;regarding the use of&#x000a0;imdevimab during breastfeeding. According to the emergency use authorization, the decision to breastfeed during therapy should depend on the benefit of treatment of the mother and the benefits and risk of exposure to the infant.</p>
          </list-item>
          <list-item>
            <p>No dose adjustment is recommended for pregnant or lactating patients per emergency use authorization by the FDA (FDA 2021).<xref ref-type="bibr" rid="article-132925.r11">[11]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132925.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Imdevimab&#x000a0;is a new monoclonal antibody authorized for emergency use by the FDA due to the ongoing COVID-19 pandemic. As a novel agent, all interprofessional healthcare team members involved in patient care need to be up to speed on the latest information regarding the use of this drug. Initial results&#x000a0;show a decreasing viral load and clinical benefit if the drug is initiated early in high-risk patients with mild to moderate disease.<xref ref-type="bibr" rid="article-132925.r9">[9]</xref>&#x000a0;More adverse effects related to the drug might be reported in the future. Therefore, when the drug is being used, close safety monitoring is needed by the prescribing clinician and the nurses and pharmacists. Providers should be vigilant of any potential drug-related adverse effects. The patient's education regarding the drug is crucial.&#x000a0;</p>
        <p>The drug combination is administered via&#x000a0;intravenous&#x000a0;infusion or SQ, and there is the possibility of infusion and injection-related side effects, including&#x000a0;pyrexia, chills, urticaria, pruritis, abdominal pain, and flushing, along with hypersensitivity and anaphylaxis. Observation in the infusion center after transfusion for at least 60 minutes is recommended.&#x000a0;The&#x000a0;interprofessional team of healthcare professionals&#x000a0;must have the necessary medications and equipment in the room to ensure safe outcomes. Proper and prompt intervention can be life-saving in cases of something as serious as anaphylaxis.<xref ref-type="bibr" rid="article-132925.r7">[7]</xref>&#x000a0;Pharmacists can help clinicians and nurses ensure proper dosing, monitor drug interactions, and educate patients and staff on potential side effects. Proper collaboration between all interprofessional healthcare team members, including clinicians, infectious disease specialists, mid-level practitioners, nurses, and pharmacists, helps achieve optimal patient outcomes while minimizing patient risks.</p>
      </sec>
      <sec id="article-132925.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132925&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132925">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132925/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132925">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-132925.s10">
        <title>References</title>
        <ref id="article-132925.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurt</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Neutralizing Antibody Therapeutics for COVID-19.</article-title>
            <source>Viruses</source>
            <year>2021</year>
            <month>Apr</month>
            <day>07</day>
            <volume>13</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33916927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ajithdoss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Copin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Negron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Musser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Atwal</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Oyejide</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goez-Gazi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dutton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clemmons</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staples</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Bartley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klaffke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alfson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carrion</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pessaint</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Porto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Greenhouse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.</article-title>
            <source>Science</source>
            <year>2020</year>
            <month>Nov</month>
            <day>27</day>
            <volume>370</volume>
            <issue>6520</issue>
            <fpage>1110</fpage>
            <page-range>1110-1115</page-range>
            <pub-id pub-id-type="pmid">33037066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reichert</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to watch in 2021.</article-title>
            <source>MAbs</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>1860476</fpage>
            <pub-id pub-id-type="pmid">33459118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rajnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dulebohn</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Di Napoli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Features, Evaluation, and Treatment of Coronavirus (COVID-19)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">32150360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <article-title>An EUA for casirivimab and imdevimab for COVID-19.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <day>28</day>
            <volume>62</volume>
            <issue>1614</issue>
            <fpage>201</fpage>
            <page-range>201-202</page-range>
            <pub-id pub-id-type="pmid">33451174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singanayagam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Charlett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lopez Bernal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saliba</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ladhani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zambon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020.</article-title>
            <source>Euro Surveill</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>32</issue>
            <pub-id pub-id-type="pmid">32794447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallotta</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal antibodies for treating COVID-19.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">33597176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fulton</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Wloga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Copin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pascal</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lanza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Negron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Atwal</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.</article-title>
            <source>Science</source>
            <year>2020</year>
            <month>Aug</month>
            <day>21</day>
            <volume>369</volume>
            <issue>6506</issue>
            <fpage>1014</fpage>
            <page-range>1014-1018</page-range>
            <pub-id pub-id-type="pmid">32540904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinreich</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sivapalasingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Musser</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rofail</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hosain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kampman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kowal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DiCioccio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lipsich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Braunstein</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <collab>Trial Investigators</collab>
            </person-group>
            <article-title>REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>21</day>
            <volume>384</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-251</page-range>
            <pub-id pub-id-type="pmid">33332778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmeira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Quinello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silveira-Lessa</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zago</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Carneiro-Sampaio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>IgG placental transfer in healthy and pathological pregnancies.</article-title>
            <source>Clin Dev Immunol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>985646</fpage>
            <pub-id pub-id-type="pmid">22235228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132925.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Imdevimab</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">33226741</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
